Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Wrong proteins targeted in battle against cancer?

02.10.2002


Lasker recipient James E. Darnell contends drug developers should focus more on ’transcription factor’ proteins



Researchers may be looking for novel cancer drugs in the wrong places, says Rockefeller University Professor James E. Darnell, Jr., M.D., in an article in this month’s Nature Reviews Cancer.

Darnell, who received the 2002 Albert Lasker Award for Special Achievement in Medical Science, argues that drug development research should focus more on a specific group of proteins - called transcription factors - known to be overactive in almost all human cancers.


"The facts indicate that a limited number of transcription factors are indeed overactive in many cancers and that these overactive proteins themselves are appropriate drug targets," says Darnell, head of the Laboratory of Molecular Cell Biology at Rockefeller and co-author of the popular textbook Molecular Cell Biology.

These transcription factors include STAT3, discovered by Darnell and colleagues in 1994, STAT5, NF-kappaB, B-catenin, Notch, GLI and c-JUN - all of which play significant roles in a wide variety of cancers.

According to Darnell, drug developers continue to largely ignore these seemingly universal molecules of cancer because, unlike other cancer-causing proteins called protein kinases, transcription factors do not posses "active sites" or pockets that can be easily fitted with small inhibitory drugs.

Instead, drugs designed against transcription factors would have to target protein-protein interactions - which, because of their larger surface areas, are much harder to disrupt.

Still, Darnell argues that, despite inherent obstacles, such an approach could potentially yield novel cancer therapeutics.

"After all," he asks, "What is the benefit to medicine in all the twenty-first century promise of proteomics if we cannot selectively inhibit protein-protein interactions?"

Many of the transcription factors involved in cancer normally allow a healthy cell to respond to signals from the external environment by activating the "expression" of certain genes, which then leads to the production of new proteins. In cancer - which is characterized by cell growth gone awry - genetic mutations cause these proteins, also referred to as "oncogenic proteins," to become unusually active.

Therefore, drugs designed to block or decrease their surplus activity might effectively treat this disease.

"Transcription factors are attractive targets because they are both less numerous than other signaling activators and are at a focal point of many cancer pathways," says Darnell.

"Like kicking Achilles in the heel, striking at these targets would constitute a more global approach to fighting cancer."

In the past, drug developers in search of cancer therapeutics have placed a large focus on cancer-causing molecules called protein kinases, primarily because their active sites - tiny crevices where small molecules normally bind and activate the protein - can be easily blocked with small molecule drugs. The drug Gleevec, for example, can temporarily treat chronic myeloid leukemia by fitting into and plugging up the active site of a protein kinase, called the Ableson kinase, associated with this disease.

But, according to Darnell, this approach has two main drawbacks. First, as is the case with Gleevec, resistance to the drugs can develop, and, second, each of the protein kinases tends to be associated with only a limited number of cancer types.

Darnell argues that both of these obstacles could possibly be overcome by instead targeting certain transcription factors. He says that these proteins should not develop resistance to drugs as fast as protein kinases, and, because they are common to many cancers, drugs designed to block them should work against a diverse range of cancer types.

The final challenge is then how to target molecules that lack the convenient active sites of protein kinases. Drugs directed against transcription factors would have to prevent them from binding to one of their two primary molecular targets: DNA or proteins. To turn on specific genes, transcription factors must bind to other proteins as well as to DNA.

Since past efforts to develop drugs that disrupt DNA-protein interactions have failed, Darnell believes that targeting protein-protein interactions is the next logical step.

"With the availability of robotic screening procedures, huge chemical libraries need to be screened for small molecules that target any of the specific protein-protein interactions of transcription factors," he says.

"Even though this approach is more difficult," he adds, "It has proved practical in one preliminary case, and furthermore many inventive technologies from chemistry labs around the world give hope that this approach has great possibilities."

Whitney Clavin | EurekAlert!
Further information:
http://www.rockefeller.edu/

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

Im Focus: Small collisions make big impact on Mercury's thin atmosphere

Mercury, our smallest planetary neighbor, has very little to call an atmosphere, but it does have a strange weather pattern: morning micro-meteor showers.

Recent modeling along with previously published results from NASA's MESSENGER spacecraft -- short for Mercury Surface, Space Environment, Geochemistry and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

Conference Week RRR2017 on Renewable Resources from Wet and Rewetted Peatlands

28.09.2017 | Event News

 
Latest News

A single photon reveals quantum entanglement of 16 million atoms

16.10.2017 | Physics and Astronomy

The melting ice makes the sea around Greenland less saline

16.10.2017 | Earth Sciences

On the generation of solar spicules and Alfvenic waves

16.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>